Clinical Trials for Cervical Cancer


CPTAC III: Clinical Proteomic Analysis Consortium – Phase III Tissue Source Site Phase N/A Principal Investigator Mutch, David Disease Site Corpus Uteri


First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors Phase I/II Principal Investigator Ward, Jeffrey Disease Site Breast; Cervix; Corpus Uteri; Ill-Defined Sites; Lip, Oral Cavity…


A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer Phase III (Cancer Control) Principal Investigator Thaker, Premal Disease Site Cervix Learn…